Sdox, a H2S releasing anthracycline, with a safer profile than doxorubicin toward vasculature.
Sign Up to like & getrecommendations! Published in 2022 at "Vascular pharmacology"
DOI: 10.1016/j.vph.2022.106969
Abstract: Sdox is a synthetic H2S-releasing doxorubicin (Dox) less cardiotoxic and more effective than Dox in pre-clinical, Dox-resistant tumour models. The well-known anthracycline vascular toxicity, however, might limit Sdox clinical use. This study aimed at evaluating… read more here.
Keywords: h2s releasing; hy926 cells; sdox; h2s ... See more keywords